

**Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4)
Recombinant Antibody
Catalog # APR10973****Specification**

Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	Q8NHJ6
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG
Calculated MW	150 KDa

Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) - Additional Information**Target/Specificity**

LILRB4 / ILT3 / CD85k

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) - Protein Information**Name** LILRB4**Synonyms** ILT3, LIR5**Function**

Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance (PubMed:11875462). Receptor for FN1 (PubMed:34089617). Receptor for apolipoprotein APOE (PubMed:30333625). Receptor for ALCAM/CD166 (PubMed:29263213). Inhibits

receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:9151699). Inhibits FCGR1A/CD64-mediated monocyte activation by inducing phosphatase-mediated down-regulation of the phosphorylation of multiple proteins including LCK, SYK, LAT and ERK, leading to a reduction in TNF production (PubMed:19833736). This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:34089617). Inhibits T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytotoxic T cells and enhancing the generation of CD8+ T suppressor cells (PubMed:16493035, PubMed:19833736, PubMed:29263213). Induces up-regulation of CD86 on dendritic cells (PubMed:19860908). Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation (PubMed:11875462).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Note=Ligand binding leads to internalization and translocation to an antigen-processing compartment

Tissue Location


Detected on monocytes, macrophages, dendritic cells, natural killer cells and B-cells (at protein level). Expressed in the lung.


Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) - Images





Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) is more than 95% ,determined by SEC-HPLC.